Significance of the "delayed hyperintense portal vein sign" in the hepatobiliary phase MRI obtained with Gd-EOB-DTPA

Journal of Magnetic Resonance Imaging

Volumn 36, Issue 3, 2012, Pages 678-685

  Lee, Nam Kyung ^a   Kim, Suk ^a   Kim, Gwang Ha ^a   Heo, Jeong ^a   Seo, Hyung Il ^a   Kim, Tae Un ^b   Kang, Dae Hwan ^c  

^a Pusan National University Hospital   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Pusan National University Yangsan Hospital   (South Korea)

Author keywords

Gd EOB DTPA; liver function; MRI; portal vein

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GADOXETIC ACID; LIVER ENZYME;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CANCER; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; BILE DUCT STONE; BILIRUBIN BLOOD LEVEL; BLOOD ANALYSIS; FEMALE; GALLBLADDER CANCER; HEPATOBILIARY RADIOGRAPHY; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FUNCTION; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PORTAL VEIN; PRIORITY JOURNAL;

ADULT; AGED; DIGESTIVE SYSTEM DISEASES; FEMALE; FIDUCIAL MARKERS; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; PORTAL VEIN; PREVALENCE; REPRODUCIBILITY OF RESULTS; REPUBLIC OF KOREA; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84865338429     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23700     Document Type: Article

References (17)

1. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195: 785-792.
2. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 1996; 199: 177-183. (Pubitemid 26098637)
3. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008; 18: 457-467. (Pubitemid 351248177)
4. Kim SH, Kim SH, Lee J, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. Am J Roentgenol 2009; 192: 1675-1681.
5. Lee NK, Kim S, Lee JW, et al. Biliary MR imaging with Gd-EOB-DTPA and its clinical applications. Radiographics 2009; 29: 1707-1724.
6. Kim T, Murakami T, Hasuike Y, et al. Experimental hepatic dysfunction: evaluation by MRI with Gd-EOB-DTPA. J Magn Reson Imaging 1997; 7: 683-688. (Pubitemid 28365618)
7. Ryeom HK, Kim SH, Kim JY, et al. Quantitative evaluation of liver function with MRI Using Gd-EOB-DTPA. Korean J Radiol 2004; 5: 231-239.
8. Motosugi U, Ichikawa T, Sou H, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 2009; 30: 1042-1046.
9. Tajima T, Takao H, Akai H, et al. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr 2010; 34: 362-366.
10. Takao H, Akai H, Tajima T, et al. MR imaging of the biliary tract with Gd-EOB-DTPA: Effect of liver function on signal intensity. Eur J Radiol 2011; 77: 325-329.
11. Brismar TB, Dahlstrom N, Edsborg N, Persson A, Smedby O, Albiin N,. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers. Acta Radiol 2009; 50: 709-715.
12. Zizka J, Klzo L, Ferda J, Mrklovsky M, Bukac J,. Dynamic and delayed contrast enhancement in upper abdominal MRI studies: comparison of gadoxetic acid and gadobutrol. Eur J Radiol 2007; 62: 186-191. (Pubitemid 46560352)
13. Schuhmann-Giampieri G, Mahler M, Roll G, Maibauer R, Schmitz S,. Pharmacokinetics of the liver-specific contrast agent Gd-EOB-DTPA in relation to contrast-enhanced liver imaging in humans. J Clin Pharmacol 1997; 37: 587-596. (Pubitemid 27443539)
14. Kamisako T, Kobayashi Y, Takeuchi K, et al. Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance. J Gastroenterol 2000; 35: 659-664.
15. Cruite I, Schroeder M, Merkle EM, Sirlin CB,. Gadoxetate disodium-enhanced MRI of the liver. Part 2. Protocol optimization and lesion appearance in the cirrhotic liver. Am J Roentgenol 2010; 195: 29-41.
16. Reddy KR, Kligerman S, Levi J, et al. Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg 2001; 67: 173-178. (Pubitemid 33738212)
17. Ringe KI, Husarik DB, Sirlin CB, Merkle EM,. Gadoxetate disodium-enhanced MRI of the liver. Part 1. Protocol optimization and lesion appearance in the noncirrhotic liver. Am J Roentgenol 2010; 195: 13-28.